Gene · 5892
Papers2,681
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,681
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prevalence of pathogenic germline variants and indications for testing in a diverse community-based endometrial cancer cohort. | Gynecol Oncol | 2026 | 42822083 | PubTator, text mining | PubMed |
| Genetic risk factors in Early-Onset Gastric Cancer: A systematic review and meta-analysis. | Cancer Genet | 2026 | 42801866 | PubTator, text mining | PubMed |
| Breast-Ovarian Hereditary Cancer Syndrome: Beyond BRCA1 and BRCA2. | Curr Oncol | 2026 | 42782902 | PubTator, text mining | PubMed |
| Distinct functions of mammalian RAD51 paralogs in genome maintenance. | Biochem Soc Trans | 2026 | 42682019 | PubTator, text mining | PubMed |
| Risk-reducing gynecologic surgery in non-BRCA cancer predisposition mutations: a multi-institutional study. | Int J Gynecol Cancer | 2026 | 42648957 | PubTator, text mining | PubMed |
| Exome-based cancer driver gene comprehensive testing can provide a genetic diagnosis for individuals with triple-negative breast cancer. | PLoS One | 2026 | 42636242 | PubTator, text mining | PubMed |
| From genetic testing to prevention: an integrated clinical pathway for hereditary risk assessment in tubo-ovarian cancer. | Int J Gynecol Cancer | 2026 | 42617415 | PubTator, text mining | PubMed |
| Uncovering Hereditary Risk: Germline Homologous Recombination Repair Variant Spectrum in a Large North Indian Cancer Cohort (INSIGHT-HRR). | JCO Glob Oncol | 2026 | 42594331 | PubTator, text mining | PubMed |
| PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers. | Int J Mol Sci | 2026 | 42589411 | PubTator, text mining | PubMed |
| Genomic Alterations and Their Clinical Implications in Pancreatic Ductal Adenocarcinoma in a Large-Scale Chinese Cohort. | Cancer Med | 2026 | 42487270 | PubTator, text mining | PubMed |
| [Analysis of homologous recombination deficiency testing in ovarian cancer based on next-generation sequencing]. | Zhonghua Zhong Liu Za Zhi | 2026 | 42477931 | PubTator, text mining | PubMed |
| Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States. | Urol Oncol | 2026 | 42431822 | PubTator, text mining | PubMed |
| Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or with empirically increased breast cancer risk. | Breast Cancer Res Treat | 2026 | 42430009 | PubTator, text mining | PubMed |
| Routine germline genetic testing in 3552 unselected NHS breast cancer patients: evidence informing testing criteria and implementation of a 'BRCA-DIRECT' mainstreaming pathway. | NPJ Breast Cancer | 2026 | 42426004 | PubTator, text mining | PubMed |
| Germline Multigene Panel Testing in Women With Invasive Lobular Cancer. | JAMA Netw Open | 2026 | 42418202 | PubTator, text mining | PubMed |
| Frequency of germline pathogenic variants in breast cancer predisposing genes in a national cohort of young women with breast cancer. | Br J Cancer | 2026 | 42337046 | PubTator, text mining | PubMed |
| Saturation Genome Editing reveals the functional impact of RAD51D and XRCC2 variants. | bioRxiv | 2026 | 42327150 | PubTator, text mining | PubMed |
| Monoallelic germline RAD51C, RAD51D, and BRIP1 variants in hereditary cancer testing: Variant spectrum and clinical counselling implications. | Mutat Res | 2026 | 42322921 | PubTator, text mining | PubMed |
| Hereditary Cancer Genetic Testing for All? A Retrospective Analysis on Genetic Mutations Found in Individuals Not Meeting NCCN® Guidelines. | Eur J Breast Health | 2026 | 42317085 | PubTator, text mining | PubMed |
| Impact of germline RAD51D mutations on breast cancer: Susceptibility to DNA-damaging agents. | Mol Ther Oncol | 2026 | 42306566 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5892/papers